Literature DB >> 27988100

Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.

Benjamin Solomon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27988100     DOI： 10.1016/j.jtho.2016.11.2214

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.

Authors:  Wenxian Wang; Hong Wang; Peihua Lu; Zongyang Yu; Chunwei Xu; Wu Zhuang; Zhengbo Song
Journal:  J Transl Med       Date:  2019-02-21       Impact factor: 5.531

2.  Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.

Authors:  Naifu Nie; Haodong Zhou; Kejun Zhang; Lan Liu; Nuo Luo; Renyuan Wang; Xin Li; Mengxiao Zhu; Chen Hu; Yubo Wang; Zhulin Liu; Li Li; Yong He
Journal:  Thorac Cancer       Date:  2022-07-27       Impact factor: 3.223

3.  Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.

Authors:  Mary B Kelley; Taylor J Geddes; Maria Ochiai; Noah M Lampl; W Wade Kothmann; Sara R Fierstein; Victoria Kent; Kathleen DeCicco-Skinner
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.